减肥
内分泌学
内科学
医学
受体
血糖性
糖尿病
肥胖
兴奋剂
胰高血糖素样肽1受体
2型糖尿病
药理学
作者
Isabella Zaffina,Maria Chiara Pelle,Giuseppe Armentaro,Federica Giofrè,Velia Cassano,Angela Sciacqua,Franco Arturi
标识
DOI:10.3389/fendo.2023.1095753
摘要
The occurrence of obesity is an increasing issue worldwide, especially in industrialized countries. Weight loss is important both to treat obesity and to prevent the development of complications. Currently, several drugs are used to treat obesity, but their efficacy is modest. Thus, new anti-obesity treatments are needed. Recently, there has been increased interest in the development of incretins that combine body-weight-lowering and glucose-lowering effects. Therefore, a new drug that simultaneously coactivates both the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) has been developed. Tirzepatide, the first in this class, improves glycemic control by increasing insulin sensitivity and lipid metabolism as well as by reducing body weight. Combining the activation of the two receptors, greater improvement of β-cell function offers more effective treatment of diabetes and obesity with fewer adverse effects than selective GLP-1R agonists. In the present review, we discuss the progress in the use of GIPR and GLP-1R coagonists and review literature from in vitro studies, animal studies, and human trials, highlighting the synergistic mechanisms of tirzepatide.
科研通智能强力驱动
Strongly Powered by AbleSci AI